David A. Siegel Adverum Biotechnologies, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.75 - $1.26 $22,800 - $38,304	-30,400 Reduced 6.17%	462,300 $346,000
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.33 $98,250 - $152,615	65,500 Added 15.33%	492,700 $739,000
Q2 2023 Aug 14, 2023	SELL	$0.68 - $1.59 $169,173 - $395,568	-248,785 Reduced 36.8%	427,200 $679,000
Q1 2023 May 15, 2023	SELL	$0.62 - $0.85 $33,923 - $46,507	-54,715 Reduced 7.49%	675,985 $486,000
Q4 2022 Feb 14, 2023	SELL	$0.54 - $10.3 $173,394 - $3.31 Million	-321,100 Reduced 30.53%	730,700 $423,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $434,688 - $4.38 Million	-452,800 Reduced 30.09%	1,051,800 $999,000
Q2 2022 Aug 15, 2022	BUY	$0.81 - $1.34 $1,053 - $1,742	1,300 Added 0.09%	1,504,600 $1.81 Million
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $487,695 - $773,175	-396,500 Reduced 20.87%	1,503,300 $1.97 Million
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $231,246 - $318,960	132,900 Added 7.52%	1,899,800 $3.34 Million
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $1.65 Million - $2.85 Million	791,700 Added 81.18%	1,766,900 $3.83 Million
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $269,808 - $847,968	80,300 Added 8.97%	975,200 $3.41 Million
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $340,768 - $528,448	-36,800 Reduced 3.95%	894,900 $8.82 Million
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $132,840 - $192,510	13,500 Added 1.47%	931,700 $10.1 Million
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $9.34 Million - $19.6 Million	906,600 Added 7815.52%	918,200 $9.46 Million
Q2 2020 Aug 14, 2020	SELL	$8.53 - $25.64 $46,062 - $138,456	-5,400 Reduced 31.76%	11,600 $242,000
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $8,778 - $17,952	-1,100 Reduced 6.08%	17,000 $166,000
Q4 2019 Feb 14, 2020	BUY	$5.12 - $12.22 $92,672 - $221,182	18,100 New	18,100 $209,000
Q3 2019 Nov 14, 2019	SELL	$5.24 - $15.89 $395,096 - $1.2 Million	-75,400 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$5.1 - $11.89 $379,950 - $885,805	-74,500 Reduced 49.7%	75,400 $897,000
Q1 2019 May 15, 2019	SELL	$3.03 - $6.02 $251,489 - $499,659	-83,000 Reduced 35.64%	149,900 $785,000
Q4 2018 Feb 14, 2019	BUY	$2.87 - $5.92 $55,104 - $113,664	19,200 Added 8.98%	232,900 $734,000
Q3 2018 Nov 14, 2018	SELL	$4.5 - $7.6 $31,950 - $53,960	-7,100 Reduced 3.22%	213,700 $1.29 Million
Q2 2018 Aug 14, 2018	BUY	$5.3 - $6.9 $493,430 - $642,390	93,100 Added 72.91%	220,800 $1.17 Million
Q1 2018 May 15, 2018	BUY	$3.65 - $7.95 $219,730 - $478,590	60,200 Added 89.19%	127,700 $741,000
Q4 2017 Feb 14, 2018	BUY	$2.85 - $3.95 $192,375 - $266,625	67,500	67,500 $236,000

Others Institutions Holding ADVM

# of Institutions

Shares Held

524K

Call Options Held

Put Options Held

Versant Venture Management, LLC San Francisco, CA

507K
Shares

$2.4 Million
9.32% of portfolio
Pinz Capital Management, LP New York, NY

15.7K
Shares

$74,418
0.03% of portfolio
American Portfolios Advisors Holbrook, NY

1.15K
Shares

$5,451
0.0% of portfolio

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account